SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U.S. pharmaceutical wholesalers, moving its second FDA-approved commercial product into nationwide distribution.
Key Investor Takeaways
- SCIENTURE (NASDAQ:SCNX) has begun commercial sales of REZENOPY, shifting the product from market preparation to active distribution.
- REZENOPY is the highest-dose FDA-approved naloxone hydrochloride nasal spray in the U.S., delivering 10 mg in a single-use device.
- The company cited an approximately $143 million U.S. naloxone market covering 9.8 million units, based on IQVIA MAT June 2026 data.
- Commercial payer coverage has the potential to reach more than 100 million covered lives, while GPO agreements provide access to over 5,000 healthcare facilities.
- REZENOPY becomes SCIENTURE’s second FDA-approved commercial product, expanding the company’s portfolio of revenue-generating assets.
Why SCNX Stock Is in Focus
SCIENTURE has fulfilled its first REZENOPY purchase orders to U.S. pharmaceutical wholesalers and commenced nationwide distribution, marking the start of commercial execution for the product.
REZENOPY is approved for the emergency treatment of known or suspected opioid overdose in adult and pediatric patients. The product delivers 10 mg of naloxone hydrochloride in a single-use nasal spray, making it the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States, according to the company.
SCIENTURE has deployed a dedicated national sales team targeting hospitals, emergency medical services, rehabilitation centers, pharmacies, public health agencies and other healthcare providers.
The company also enters the launch with commercial payer coverage potentially reaching more than 100 million covered lives. Its GPO agreements provide access to more than 5,000 healthcare facilities, which SCIENTURE says represents potential penetration of over 60% of the U.S. institutional naloxone market.
SCIENTURE holds exclusive U.S. commercialization rights to REZENOPY through a March 2025 agreement with Summit Biosciences, a Kindeva subsidiary. The product received FDA approval in April 2024.
Why This Matters for Investors
The commercial launch changes the REZENOPY story from one centred on regulatory approval and market preparation to one focused on adoption and revenue generation.
That distinction may be significant for (NASDAQ:SCNX) because REZENOPY expands the number of FDA-approved products in its commercial portfolio to two. Management also expects the product to use infrastructure already established across manufacturing, supply chain, distribution and market access, potentially increasing the strategic value of those existing capabilities as the portfolio grows.
The addressable market provides another point of focus. SCIENTURE cited IQVIA data showing approximately $143 million in annual U.S. naloxone sales across 9.8 million units as of June 2026. The combination of payer coverage, institutional purchasing agreements and a dedicated sales force gives the company established channels through which it can pursue that opportunity.
However, access does not itself establish adoption. For investors, the next stage is likely to depend on SCIENTURE’s ability to convert its distribution footprint and institutional availability into product uptake. The release does not provide REZENOPY revenue guidance or sales targets, leaving commercial performance as an important measure of execution.
What to Watch Next
Attention now shifts to evidence of REZENOPY adoption following the initial purchase orders. Updates on institutional utilization, additional market access and the product’s contribution to SCIENTURE’s revenue could help indicate the effectiveness of the launch.
Investors can also watch whether SCIENTURE expands REZENOPY’s commercial reach during the remainder of 2026 and how effectively its existing infrastructure supports growth across a broader portfolio of marketed specialty pharmaceutical products.